RIGL

Rigel Pharmaceuticals Inc

• TipRanks·06/02 11:17

  Pantginis Reiterates Buy on Rigel, Citing Strengthening Oncology Portfolio and Unchanged $57 Price Target

• Dow Jones·06/02 11:12

  Rigel Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

• Seeking Alpha·06/01 14:20

  These 10 small-cap U.S. healthcare giants rank among the market's most attractively valued stocks

• PUBT·05/28 20:20

  Rigel Pharma director Kamil Ali-Jackson disposes of 2,500 common shares worth $72,925

• PUBT·05/27 23:02

  Knight Therapeutics launches Tavalisse in Mexico for chronic immune thrombocytopenia

• Dow Jones·05/27 15:12

  Rigel Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

• Benzinga·05/27 15:02

  HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

• TipRanks·05/27 14:54

  Rigel partner Kissei submits new drug application for olutasidenib in Japan

• TipRanks·05/27 14:52

  H.C. Wainwright highlights Rezlidhia NDA as expanding Rigel’s ex-U.S. reach

• PUBT·05/27 12:07

  Rigel CEO to Present Company Overview at Jefferies Global Healthcare Conference

• TipRanks·05/22 16:30

  Lilly and Rigel Advance RA Pipeline as Key LY3871801 Mid-Stage Trial Reaches Completion

• Dow Jones·05/22 11:01

  Rigel Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

• Benzinga·05/22 10:51

  HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

• TipRanks·05/22 10:27

  Rigel: Buy Rating Reiterated as New Oncology Data Support Franchise Strength and Unchanged $57 Price Target

• PUBT·05/21 21:18

  Rigel says Phase 3 AcceleRET-Lung trial meets primary endpoint for GAVRETO in NSCLC